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A quimioterapia é o único procedimento farmacológico validado para a terapêutica da 
leishmaniose e da malária, consideradas doenças negligenciadas para o desenvolvimento de fármacos 
pelas indústrias farmacêuticas. Com a não renovação medicamentosa, o surgimento de resistência, 
os efeitos colaterais e o longo período de tratamento indicam a necessidade do desenvolvimento de 
novos e mais eficientes fármacos. A Floresta Amazônica é a região com a maior biodiversidade do 
planeta, com uma riqueza de animais e plantas produtoras de moléculas com atividades biológicas 
relevantes para o desenvolvimento e exploração biotecnológica. Algumas destas moléculas, obtidas de 
extratos vegetais e de venenos de anuros, apresentam atividade leishmanicida e plasmodicida, o que 
demonstra o potencial desta biodiversidade para a investigação de novas drogas. A moderna abordagem 
na pesquisa de novos fármacos envolve a associação de química combinatória, high-throughput 
screening, bioinformática, interação molecular, cristalografia e o estudo dinâmico de toxicidade 
sistêmica e celular, que atualmente no Brasil, estão distribuídas em poucos grupos acadêmicos 
sem a devida associação industrial. Esta deficiência, agregada ao excesso de regulamentação para 
o acesso ao material biológico, sobretudo, proveniente de unidades de conservação, populações 
tradicionais e nações indígenas, é um importante entrave para o desenvolvimento deste tipo de 
pesquisa. A associação de grupos de pesquisa do Brasil, estimulados por políticas governamentais 
de financiamento acadêmico e industrial, são essenciais para a superação destas dificuldades, de 
forma que nos próximos anos possam surgir novos produtos para terapia de doenças negligenciadas 
oriundas da biodiversidade amazônica. 
Chemotherapy is the only validated therapy for the treatment for the neglected diseases 
leishmaniasis and malaria. However, the emergence of drug resistance, collateral effects and long-
term treatment encourage the development of new and more efficient drugs. The Amazon tropical 
forest includes the richest areas of biodiversity in the world, including a great number of microbes, 
plant and animal species that produce a source of interesting biologically active molecules. 
Several of these molecules, obtained from plant extracts and frog venom have leishmanicidal and 
plasmodicidal activity, highlighting the potential of this biodiversity for the development of new 
drugs. In research, modern approaches in new drug development are carried out using combinatorial 
chemistry, high-throughput screening, bioinformatics, molecular interaction, crystallography and 
dynamic studies of cellular and systemic toxicity. In Brazil, these techniques are mainly present 
in only a few academic groups with no efficient connection to industry. The problem associated 
with over-regulation for accessing the biological material in restricted areas, local populations and 
indigenous areas places major barriers in the path of research and development of new drugs. Thus, 
the association of academic research groups in Brazil, encouraged and supported by government and 
industry, is essential to overcome these major barriers related to the development of new products 
for treatment of neglected diseases from Amazonian biodiversity in future years.
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development 
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1. Amazonian Biodiversity 
Biological diversity is not evenly distributed across 
the planet. Tropical rainforests of the world are the most 
species-rich biome, and probably include more than half 
of the number of species on earth. Approximately 70% of 
the world’s species are distributed in only 12 countries: 
Australia, Brazil, China, Colombia, Ecuador, India, 
Indonesia, Madagascar, Mexico, Peru, and Zaire.1-3 Tropical 
forests in the Americas are consistently more species rich 
than those in Africa and Asia.4 As the largest tract of tropical 
rainforest in the Americas, the Amazon tropical forest has 
unparalleled biodiversity richness, comprising the richest 
biodiversity area in the world, including a great number 
of microbes and plant and animal species.4-9 Frequently, 
new species are added to a truly huge diversity list. Recent 
compilations indicate at least 40,000 plant species, 427 
mammals, 1294 birds, 378 reptiles, 427 amphibians, and 
around 3,000 fishes have been scientifically classified in 
the region.10 
It is believed that one third of the world’s species 
inhabit the Amazon tropical rainforest, however one of 
the great gaps in Amazonian knowledge is the cataloguing 
and taxonomy of plants.11 Actually it is estimated that the 
distribution of unknown flora in the Amazon has long 
been underestimated and that plant biodiversity probably 
includes at least 3 times more plant species in the Amazon 
than are currently known.11
1.1 Biodiversity and drug development
Plants offer a vast source of molecules that present 
different effects in human homeostasis.12 These molecules, 
called natural products, have been extensively recognized 
as an important source of most of the active components 
in therapeutically effective medicines. One of the reasons 
for this success is, most of the time, natural products are 
more readily absorbed than synthetic drugs.13 Before the 
advent of high-throughput screening and post-genomic 
technologies more than 80% of drug substances were 
natural products or inspired by a natural compound.14 
This fact illustrates the importance of natural products for 
human health. 
Natural products are not always used just as medical 
products but their actions has also helped reveal important 
aspect of physiology by interactions with membrane 
channels, receptors and metabolic pathways.13-16
Comparising information available on sources of new 
drugs from 1981 to 200717,18 has indicated that almost half 
of the drugs approved since 1994 are based on natural 
products.13 Between the years of 1981 to 2006, the U. S. 
Food and Drug Administration (FDA) has approved 1184 
new drugs among wich 609 (51.4%) were natural-products-
related: 55 of them were natural products, 270 derived 
from a natural product by semisynthetic modification, 52 
made by total synthesis were the pharmacophore came 
from a natural product, and 232 were sythetized mimicking 
a natural product.19 Comparisons of the information 
presented on sources of new drugs from 1981 to 200718,19 
indicate that almost half of the drugs approved since 1994 
are based on natural products. Thirteen natural-product-
related drugs were approved from 2005 to 200718 and, as 
pointed out by Butler,18 five of these represented the first 
members of new classes of drugs: the peptides exenatide 
and ziconotide, and the small molecules ixabepilone, 
retapamulin and trabectedin.13
Despite the advantages of natural products and 
past successes, many large pharmaceutical companies 
have scaled back the use of natural products in drug 
discovery screening.13 This has been because of the noted 
disadvantages of their use that include the difficulties 
in sourcing and supply, complexities of natural product 
chemistry and the inherent delay of working with them, 
together with complications connected to legal regulation 
involving intellectual property rights, access to genetic 
resources, traditional knowledge and related benefit 
sharing.
Complications involving biodiversity’s legal access 
regulations in Brazil today comprise the greatest problem 
for the scientific and technological development of the 
national pharmaceutical industry in the country with the 
greatest biodiversity in the world.
According to Harvey,13 although this is a time when 
pharmaceutical companies cut back on their use of natural 
products in drug discovery, there are many promising drug 
candidates in the current development pipeline that are 
of natural origin. Technical drawbacks associated with 
natural products research have been lessened, and there 
are better opportunities to explore the biological activity 
of previously inaccessible sources of natural products. 
With the increasing acceptance that the chemical diversity 
of natural products it is essencial to provide core support 
for the development of new drugs so that in the future 
there will be further expansion in the use of drugs based 
on natural products, whether in nature or developed from 
chemical libraries.
1.2 Traditional medicine and ethnopharmacology 
Traditional medicine is a comprehensive term used 
to refer either to systems such as Chinese medicine, 
Indian ayurveda and Arabic unani medicine, or to various 
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forms used in indigenous and traditional communities. 
Traditional medicine is characterized by the use of plants, 
animals and mineral substances by arcaic communities for 
therapeutical purposes to treat various diseases.20 Studies 
of the pharmacological aspects of these medicines by 
ethnopharmacological approaches reveal several active 
components derived form plants used in these ancient 
practices, with several historic examples. 
Jesuit priests reported in the seventeenth century that 
South America Indians used a tea-like drink prepared from 
the bark of a native tree from Peru21 to treat some types 
of fever. In 1742, this tree was identified as Cinchona sp22 
(Rubiaceae) and in 1820 the alkaloid quinine was purified 
from the bark of Cinchona.22,23 A tea made from Artemisia 
annua (Asteraceae) has been used for treat intermittent 
fevers in China since 168 B.C. In 1972, the active ingredient 
artemisinin, a sesquiterpene lactone with antimalarial 
activity, was isolated from this plant. Indians from the north 
and northeast of Brazil have used oil from Copaifera spp 
(Fabaceae) since the 19th century to heal wounds and other 
skin diseases, probably, based on observations of animals 
rubbing on copaiba’s trunks.24 
Traditional medicines are widely disseminated and it is 
estimated that 80% of the world´s population depends on 
them as a primary health source.25 In Brazil, populations 
of rural areas and forests rely on popular and traditional 
medicine for treatment of many infectious diseases. Some 
species are included in prescriptions for therapeutic 
purposes such as the healing of wounds, inflammation 
due to microbial or parasitic infections, skin lesions, 
and ulcers.12 In some cases, the same plant may be used 
for different purposes.26 It is the general consensus that 
traditional medical use of several biological sources 
indicates the presence of biologically active compounds. 
Bourdy et al.27 relate their experience over years with 
different ethnic groups from South America that showed 
that whenever a strong incidence of malaria is found, then 
half of the species related as “true” antimalarials had in 
vitro and in vivo activity. In spite of that, Bourdy et al.27 
also related that harvesting season and different preparation 
protocols in the laboratory lead to different results with 
in vitro and in vivo models. Possibly, the inactivity or 
even poor activity reported in several scientific articles 
worldwide using different biological sources possess biased 
conclusions. 
1.3 Neglected diseases
Leishmania and Plasmodium are protozoan parasites 
responsible for a spectrum of diseases known as 
leishmaniasis and malaria. These diseases are classified 
as neglected diseases due to lack of financial investments 
by the world pharmaceutical industry and, when associated 
with HIV co-infection, present a serious public health 
problem in the majority of the developing countries in 
the tropical regions of the world.28 Human malaria is 
an infectious disease caused by one or more species of 
Plasmodium (i.e., P. falciparum, P. vivax, P. ovale, and P. 
malariae). Malaria remains a devastating global problem 
with 350-500 million cases reported and an estimates 
one million deaths annually, 80% of them in sub-Saharan 
Africa.29 Forty-nine percent of the world’s population 
lives in risk areas (e.g., 109 countries in Africa, Asia, the 
Middle East, Eastern Europe, Central America and South 
America, the Caribbean, and Oceania).29 Another tropical 
disease with relevant importance regarding public health 
is leishmaniasis, a broad spectrum of parasitic diseases 
caused by obligate intracellular protozoa.30-33 Leishmaniasis 
comprises two major forms: cutaneous, which causes skin 
sores, and visceral, which affects internal organs of the 
body (e.g., spleen, liver, and bone marrow). It is estimated 
that 350 million people in approximately 90 countries 
around the world are exposed to infection by Leishmania 
and that some 1.5-2 million people are infected annually.34 
In the Old World, leishmaniasis was common in Asia, the 
Middle East, Africa (particularly East and North Africa, 
with some cases elsewhere), Southern European regions, 
but not in Australia or the South Pacific. In the Americas, 
leishmaniasis occurs from Northern Mexico (seldom in the 
Southern United States) to Northern Argentina; but not in 
Chile, Uruguay and Canada. More than 90% of the world’s 
cases of cutaneous leishmaniasis are in Afghanistan, 
Algeria, Brazil, Iran, Iraq, Peru, Saudi Arabia and Syria, and 
90% of the world’s cases of visceral leishmaniasis occur in 
Bangladesh, Brazil, India, Nepal and Sudan.34
1.4 Malaria and leishmaniasis validated therapies
The first choice treatments for these diseases are 
based on a limited number of chemotherapeutic agents 
characterized by high toxicity and cost, which have 
made treatment inefficient since the 1980’s in many 
areas of high-transmission.35Quinine from Cinchona sp22 
(Rubiaceae) was the drug most used to treat malaria until 
the First World War (1914-1918). During this conflict, new 
molecules with antimalarial activity were synthesized, such 
as 9-aminoacrinidine (quinacrine, mepacrine) which was 
synthesized in the 1920’s and commercialized in 1930 under 
the name of atabrine.36 In 1944, quinine was synthesized in 
the laboratory,22 encouraging the development of several 
drugs, among them the amodiaquine, primaquine and 
chloroquine. These drugs are generally used to treat malaria 
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due to their low cost, tolerance, safety in the treatment of 
pregnant women, lack of toxic effect in recommended 
doses, and high effectiveness in curing the disease.37,38 
Chloroquine-resistant P. falciparum, first detected in 1961 
in Vietnam, was reported in several American soldiers,39 
motivating an intensive program of research for antimalarial 
new agents. Dapsone and pyrimethamine/sulfadoxine were 
introduced in prophylaxis.21,40 Pyrimethamine was also 
sold in combination with sulfalene and with dapsone.41 
Later on, two other highly effective compounds against 
strains resistant to P. falciparum were approved by the 
FDA: mefloquine42 and halofantrine.38,43 However, there 
are reports of resistance to both compounds.44-46 Pentavalent 
antimonials have been recommended for the treatment 
of leishmaniasis for over 50 years.47 Unfortunately, 
the treatment with these drugs leads to well-described 
adverse reactions, and parasite resistance to these drugs 
is increasing in some areas, where limited or no efficacy 
is observed.48,49 Diamidine pentamidine and amphotericin 
B are used as second choices for leishmaniasis treatment. 
However, the use of these drugs is limited due to their 
toxicity or unconventional administration.50 Newer drugs, 
such as the lipid formulations of amphotericin B, have been 
effective in the treatment of visceral leishmaniasis.47,51,52 
Unfortunately, the prohibitive cost of the new formulations 
of this drug inhibit its use by the majority of patients with 
visceral leishmaniasis.51 
Drug intervention is the only mechanism of malaria 
and leishmaniasis treatment approved by the World 
Health Organization. However, the chronic drug resistance 
resulting from the recommended therapy, associated 
with the collateral effects, has stimulated the search for 
alternative treatments.30,31 In addition to this long-term 
therapy associated with toxic effects for both diseases 
frequently leads to patients abandoning treatment, 
indicating the need for new drug searches.
1.5 Natural products from Amazonian biodiversity and their 
potential in chemoterapy of neglected diseases
Among natural products, the alkaloids comprise the 
largest single class of secondary plant metabolites. They 
play an important role in plant defense against a variety 
of microorganisms and animals, having a remarkable 
range of pharmacological activity. 19,53-57 These compounds 
present an enormous structural diversity. Currently, several 
alkaloids58,59 and other isolated molecules55,60-62 have 
biological activity against important parasites including 
Leishmania sp and Plasmodium sp. These parasites are the 
etiologic agents of the most important neglected diseases 
in the world. These molecules are promising candidates 
in the development of antiparasitic drugs and as tools for 
the elucidation of important metabolic pathways of these 
parasites. Extracts and purified secondary metabolites 
obtained from plants belonging to the genus Abuta 
(Menispermaceae),65 Aspidosperma (Apocynaceae),62 
Bidens (Asteraceae),63 Cinchona (Rubiaceae),64 Croton 
(Euphorbiaceae),65 Erythrina (Fabaceae),66 Picrolemma 
(Simaroubaceae),62 Piper (Piperaceae),67 Pothomorphe 
(Piperaceae),62,68,69 Quassia (Simaroubaceae),70-72 
Remijia (Rubiaceae),64 Simaba (Simaroubaceae),72,73 
Tabebuia (Bignoniaceae),74 Xylopia (Annonaceae),65 
and Zanthoxylum (Rutaceae),75 found in Amazonia, 
presented effective antimalarial activity. Some of the most 
potent molecules against Plasmodium falciparum were 
obtained from the bark and roots of Amazonian species 
belonging to these genera: neosergeolide, a terpenoid 
quassinoid from Picrolemma sprucei (Simaroubaceae);62 
simalikalactone D, a terpenoid quassinoid from Quassia 
amara (Simaroubaceae)71 and Simaba orinocensis 
(Simaroubaceae); 72 aspidocarpine,  an alkaloid 
from Aspidosperma desmanthum (Apocynaceae);62 
orinocinolide, a terpenoid quassinoid from Simaba 
orinocensis (Simaroubaceae);72 and ellipticine, an alkaloid 
from Aspidosperma vargasii (Apocynaceae).62 These 
molecules present potent antimalarial activity against 
chloroquine-resistant Plasmodium falciparum in vitro 
(IC50= 1.0, 3.7, 7.0, 8.5, and 18.0 ng mL-1 respectively). 
Other purified molecules and extracts from the genera 
Annona (Annonaceae),76 Baccharis (Asteraceae),26 
Calophyllum (Clusiaceae),77 Cassia (Fabaceae),78 
Copaifera (Fabaceae),79 Croton (Euphorbiaceae),80 
Guatteria (Annonaceae),81 Jacaranda (Bignoniaceae),82 
Lippia (Verbenaceae),26 Piper (Piperaceae),83 Plectranthus 
(Lamiaceae),26 Stachytarpheta (Verbenaceae),84 and 
Pourouma (Moraceae),85 that also have Amazonian 
species, present effective antileishmanial activity. 
Secondary metabolites isolated from Annonaceae 
plants had leishmanicidal activity against different species 
of Leishmania. Berberine, a quaternary isoquinolinic 
alkaloid found in a number of plant families (Annonaceae, 
Berberidaceae, Menispermaceae), is one of the alkaloids 
with the highest leishmanicidal activity. This metabolite 
is the main constituent in various folk remedies used in 
the treatment of cutaneous leishmaniasis, malaria and 
amoebiasis.86 Berberine has been used clinically for the 
treatment of leishmaniasis and it has been demonstrated 
that it possesses significant activity both in vitro and in vivo 
against several species of Leishmania. At a concentration 
of 10 µg mL-1 it effectively eliminates L. major parasites 
in peritoneal mice macrophages.86, 109,110
Species from the Annonaceae family have had their 
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alkaloids isolated and investigated for their leishmanicidal 
activities. The isolated compound anonaine, an 
isoquinoline alkaloid from the roots of Annona spinescens 
(Annonaceae), produces total lysis of promastigote forms 
of L. amazonensis, L. braziliensis and L. donovani with 25, 
50, and 100 µg mL-1 doses respectively.89 Liriodenine, an 
isoquinoline alkaloid from the roots and bark of Annona 
spinescens and Annona foetida (Annonaceae) exhibited 
antileishmanial activity in vitro against promastigotes of 
L. braziliensis (IC50= 34.8 µmol L-1).76 Isoguattouregidine, 
an isoquinolinic alkaloid isolated from the bark of Guatteria 
foliosa (Annonaceae), causes a total lysis of the parasites 
of L. donovani and L. amazonensis when evaluated at a 
concentration of 100 µmol L-1.89,112
The alkaloids xylopine and nornuciferine from Guatteria 
amplifolia (Annonaceae), and cryptodorine, nornantenine, 
isodomesticine, orisodomesticine, nantenine, and neolitsine 
from Guatteria dumetorum (Annonaceae) demonstrated 
significant activity against Leishmania mexicana. Xylopine 
was among the most active compounds (LD50 = 3 µmol L-1) 
and showed a 37-fold higher toxicity towards L. mexicana 
than macrophages.90 Neolitsine effectively reduced the 
parasite growth at a concentration of 15 µmol L-1.81
Rosa et al.80 investigated the leishmanicidal activity 
of the essential oil rich in the terpenic alcohol linalool 
extracted from Croton cajucara (Euphorbiaceae) against 
Leishmania amazonensis. The LD50 values of C. cajucara 
essential oil and purified linalool on the viability of 
L. amazonensis promastigotes were 8.3 ng mL-1 for 
essential oil and 4.3 ng mL-1 for purified linalool, and the 
LD50 for amastigotes were 22.0 ng mL-1 and 15.5 ng mL-1, 
respectively. These compounds have a potent leishmanicidal 
activity due to their disruption of flagellar membranes, 
mitochondrial swelling, and damages in the organization 
of the nuclear and kinetoplast chromatins. The essential 
oils were not toxic to mammalian cells and increased nitric 
oxide production by mouse peritoneal macrophages.80
Species of the Copaifera genus (Fabaceae) are 
important medicinal plants of the Amazonian region. 
They supply an oil, known as copaiba oil or balsam of 
copaiba, widely commercialized all over Brazil due to 
its anti-inflammatory and healing agent properties, as 
has been acknowledged for centuries.91-93 Trypanocidal 
and leishmanicidal activities of the copaiba oils were 
mentioned in some ethnopharmacological studies.91,92 
Santos et al.24 screened eight different kinds of Brazilian 
copaiba oils for antileishmanial activity. Oil from 
Copaifera reticulata had activity against promastigote, 
axenic amastigote and intracellular amastigote forms of 
Leishmania amazonensis, with IC50 values of 5, 15, and 
20 µg mL-1, respectively.24 
Another potential plant family, currently under 
investigations, that presents important perspectives for 
drug development is the Piperaceae family. These plants 
are widely distributed in tropical and subtropical regions 
of the world, and are often used as food flavouring 
agents, in traditional medicines, and as pest control 
agents.94 Phytochemical research carried out with 
Piper species revealed different classes of natural 
products such as alkaloids, amides, cyclopentenedione 
derivatives, dihydrochalcones, essential oils, flavonoids, 
lignans, neolignans, and phenylpropanoids.94-102 The 
bioactive products of Piper have several biological 
activities including anti-inflammatory, antimicrobial, 
antifungal, insecticidal and cytotoxic effects.103-106 
Thirteen benzoic acid derivatives isolated from Piper 
glabratum (Piperaceae) and P. acutifolium (Piperaceae) 
were evaluated in vitro against the promastigote forms of 
Leishmania spp., Trypanosoma cruzi, and Plasmodium 
falciparum.67 Among the evaluated compounds, methyl 
3,4-dihydroxy-5-(3’-methyl-2’-butenyl)benzoate exhibited 
the leishmanicidal effect (IC50 13.8-18.5 µg mL-1) 
against the three Leishmania strains used, and methyl 
3,4-dihydroxy-5-(2-hydroxy-3-methylbutenyl)benzoate, 
methyl 4-hydroxy-3-(2-hydroxy-3-methyl-3-butenyl)
benzoate, and methyl 3,4-dihydroxy-5-(3-methyl-
2-butenyl)benzoate showed significant trypanocidal 
activity, with IC50 values of 16.4, 15.6, and 18.5 µg mL-1, 
respectively. 2’,6’-Dihydroxy-4’-methoxychalcone 
(DMC) purified from the dichloromethane extract of Piper 
aduncum inflorescences was active, in in vitro assays, 
against promastigotes and intracellular amastigotes of 
Leishmania amazonensis, with IC50 of 0.5 and 24 µg mL-1, 
respectively.107,108 In our laboratory, the screening for 
compounds with antileishmanial activity from different 
Piper species, P. permucromatum, P. tuberculatum, 
P. hispidum and P. renintens has proved worthwhile in 
bioassays against promastigote forms of Leishmania 
spp. (paper in preparation). Despite the effort of some 
research groups to study natural products obtained from the 
Amazonian forest, we could not find subsequent studies of 
clinical trials reported in the literature reviwed regarding 
the above compounds.
1.6 Peptides from Amazonian anuran fauna
The Amazon forest includes the highest number of the 
anuran species of the world.109 The anuran skin presents 
morphofunctional and behavioral protective adaptations 
against a number of adverse factors in the terrestrial 
environment.110 The venom gland produces noxious or 
toxic secretions, which are rich in substances with a variety 
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of pharmacological effects.110 The complex chemical 
composition of the anuran skin secretions constitutes a 
source of biologically active compounds against bacteria, 
fungi and protozoa.111 Many of these molecules are known 
as antimicrobial peptides (AMPs). The emerging drug 
resistance of pathogenic microorganisms has stimulated 
interest in the development of antimicrobial peptides from 
anuran skin as therapeutic agents.111 Antimicrobial peptides 
compose the innate immunity system of anurans against 
microbial invasion.112-114 Crafted by evolution into an 
extremely diversified array of sequences and folds, AMPs 
do share a common amphiphilic 3-D arrangement.114 This 
feature is directly linked to a common mechanism of action 
that predominantly develops upon interaction of peptides 
with cell membranes of target cells.114 The mechanisms of 
action of AMPs in parasite membranes are complex and 
unknown, but they constitute a promising and attractive 
proposition as new antileishmanial and antimalarial 
therapeutics. The AMP mechanisms of interaction with 
the membrane are very  complex. This complexity inhibits 
a fast adaptation of parasites, requiring a change in its 
membrane structure or composition, in contrast to drugs 
of intracellular action.115
Several anuran AMPs had leishmanicidal activity 
against different species of Leishmania (Table 1).117,118 
These include the skin peptide YY (Skin-PYY) from 
Phyllomedusa bicolor (Amazon region),119 dermaseptin 
hypo01 (DShypo 01) from Phyllomedusa hypochondrialis 
(South America including Amazon region),120 dermaseptin 
S4 (DS IV) from Phyllomedusa sauvagii (Chacoan 
region) and its derivatives,121-123 dermasepin 01 (DS 01) 
from Phyllomedusa oreades (Cerrado region, Brazil),120 
magainin 2 from Xenopus laevis (Central and south 
Africa),124 and temporins A and B from Rana temporaria 
(Europe).125 Skin polypetide YY from Amazon P. bicolor 
skin reduces the viability of promastigote forms of 
Leishmania major after one hour incubation at 25 µg mL-1.119 
Dermaseptin hypo01 from Amazon P. hypochondrialis 
skin reduce to non-detectable levels the promastigote 
forms of Leishmania amazonensis at concentrations 
of near 64 µg mL-1 after 2 and 6 hour of incubation.120 
These results clearly indicate an increased interest 
in AMPs with leishmanicidal activity. Moreover, the 
anuran AMP dermaseptin S4 and its derivatives were the 
only anuran AMPs tested in vitro against Plasmodium 
falciparum displaying a considerable effectiveness 
(IC50 of 7.7 µmol L-1 for dermaseptin S4 and 5.3 µmol L-1 
for the derivate NC7-P at the ring stage, and 3.4 µmol L-1 
and 6.2 µmol L-1, respectively, for the trophozoite stage).126 
Dermaseptin S4 kills the intraerythrocytic malaria parasites 
through the lysis of the host cells, but its derivatives kill 
the parasite without lysing the erythrocyte.126,127 However, 
none of these peptides have been tested in vivo or against 
naturally acquired leishmaniasis or malaria. 
1.7 The complexity of new chemical entity (NCE) 
development through Amazonian biodiversity 
Designing a new drug to market is a time-consuming 
and expensive process for pharmaceutical companies, which 
need to identify potential targets, screening and development 
in order to maintain a competitive edge: technologies that 
require specialized expertise and infrastructure that are 
largely concentrated in pharmaceutical industries and are 
lacking in malaria and leishmania endemic countries. 
Successful drug discovery efforts include biochemical, 
biophysical, genetic, pharmacological and immunological 
humoral and cytological approaches, targeting such 
processes as signal transduction, cell cycle control, 
apoptosis, gene regulation, metastasis, and for malaria and 
leishmaniasis, the cell toxicity is highly relevant. The modern 
approaches for drug development combines a widespread use 
of combinatorial chemistry,128,129 high-throughput screening 
(HTS)130 associated with bioinformatics,131 crystallographic 
data132 and molecular-molecular docking interaction.133 The 
HTS assays could be accomplished from synthetic molecules 
Table 1. Anuran antimicrobial peptides with leishmanicidal activity
Specie Peptide Sequence
P. bicolor Skin-PYY YPPKPESPGEDASPEEMNKYLTALRHYINLVTRQRY
P. hypochondrialis DShypo 01 GLWSTIKNVGKEAAIAAGKAALGAL
P. oreades DS 01 GLWSTIKQKGKEAAIAAAKAAGQAALGAL
P. sauvagii DS IV * ALWMTLLKKVLKAAAKALNAVLVGANA
X. laevis Magainin-2 GIGKFLHSAKKFGKAFVGEIMNS
R. temporaria Temporin-A FLPLIGRVLSGIL
Temporin-B LLPIVGNLLKSLL
* Dermaseptin S4 from Phyllomedusa sauvagii also presents activity against Plasmodium falciparum.
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already registered in data banks134-138 or natural products 
(extracts or purified molecules) from biodiversity.19,139 In 
spite of the traditional impact of naturally derived medicines 
and the incredible success stories of natural products (NPs) 
as drugs from the commencement of human therapeutic 
activity to modern research and drug development, most large 
pharmaceutical companies have scaled down or terminated 
their work in natural products research.140 Some authors, 
based on statistical data, argue that the rational search of 
NPs from biodiversity is more advantageous than searching 
synthetic molecular data bases138-142 since they often display 
both unique biological properties and a challenging structural 
complexity. For example, the broad capacity of secondary 
metabolism molecules found in the plants and animal 
venoms have provided defense from infectious attacks of 
microorganisms for thousands of years.143 
Drug design by combinatorial chemistry and HTS 
created a large demand for small organic molecules that act 
on specific drug targets. These technologies focus on the 
generation of a huge number of molecules integrated with 
biological screening from a very large number of samples.137 
An increasing pressure to reduce drug development time 
and cost by the pharmaceutical industries has stimulated the 
search for relevant new molecules for commercially viable 
diseases such as cancer, cardiovascular, neural diseases and 
hospital infections but not for neglected diseases, which 
are not profitable. Even so, the pathway to be covered to 
validate a new drug from a new chemical entity (NCE) is 
exhaustive. In order to make it, the NCE must pass through 
a series of hurdles. The initial set of hurdles to overcome 
is passing from the different drug discovery stages to the 
preclinical phase (see Table 2).144 Combinatorial chemistry 
and HTS are the technologies necessary to overcome the 
discovery phase obstacles listed in Table 2. Unfortunately, 
these technologies are well implemented mainly in the 
pharmaceutical industries of developed countries, or are 
restricted to some Universities and Research Institutes.
The huge biodiversity within the Brazilian territory 
puts the country in a strategic position to rationally and 
sustainably explore NCEs for malaria, leishmaniasis and 
many other neglected or chronic diseases that possess high 
pharmaceutical commercial speculation. In the future, 
perspectives for drug design for malaria and leishmaniasis 
should focus on searching for specific parasite metabolic 
route inhibition through plant extracts and animal venoms or 
secretions screening by HTS and combinatorial chemistry. 
The basis for sustained exploration of biodiversity relies on 
clonal propagations, seed banks for preservation of genetic 
diversity145,146 or sustained animal contentions in captivity, 
i.e., if a plant/animal extract strongly binds to an enzymatic 
target, studies on the propagation of the species to supply 
biomass for extraction, fractionation and purification of 
the active metabolite(s) must initiate as soon as possible. 
However, the Amazonian biodiversity is poorly explored 
for NCE development. One of the reasons for this poor 
exploration is the lack of enough research institutions and 
qualified scientists in the Amazon region. This structural 
problem associated with the biodiversity access legal 
bureaucracy, mainly in national reserves and indigenous 
nation’s areas, creates strong hurdles to scientific exploration 
and development of the NP potential of the Amazon forest. 
2. Final Considerations 
Amazonian biomolecular diversity has a huge potential 
as a source of molecules with biological activity against 
Leishmania sp and Plasmodium sp. But it still remains an 
underexplored resource. This fact is evidenced by the large-
Table 2. The drug discovery and development process with a short definition of each stage. The processes are more complex than presented and additional 
programs such as scale up and process chemistry, statistical analysis as well as dossier preparation are important parts of the process (extracted from 
Nwaka, 2003143 with copyright permission from authors)
Level Stage Activity
Discovery Target ID/validation Find and analyze a protein target or process that can affect the outcome of disease if perturbed
Assay development Develop a method of finding what perturbs/inhibits the target
HTS Screening Test a collection of molecules to find ones that have activity
Hit-to lead Run further tests on selected molecules and begin optimization
Lead optimization Optimize molecules for relevant pharmaceutical activity
Preclinical Test molecules in animal model
Development Phase I Determine safety and dosing of the drug in humans
Phase II Obtain proof of concept of drug efficacy in humans
Phase III Characterize drug extensively in large scale human trials
Registration File a new drug application with regulatory authorities
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scale identification of compounds with antileishmanic and 
antimalaric activity from animal and plant species in other 
biomes of the world with minor biodiversity while Amazonian 
correlated species remain without research. But why does 
this region remain as an underexplored biomolecular source? 
The answer to why the scientific approach is incompatible 
with the volume of species in the Amazon region relates 
to geographical factors, and structural and legal problems. 
The Amazon region encompasses seven million square 
kilometers (1.7 billion acres), of which five and a half 
million square kilometers (1.4 billion acres) are covered 
by the rainforest. This region includes territory belonging 
to nine nations and many areas are of difficult access and 
residence. Among the structural problems is the number of 
researchers in the Amazon: according to the Coordenação 
de Aperfeiçoamento de Pessoal de Nível Superior (CAPES/
MEC), up to 2005 only one thousand PhDs were working 
in the Brazilian Amazon area,146 very few in proportion 
to the size of the area, which represents 60% of Brazilian 
territory. The number of properly equipped laboratories is 
even smaller, probably not more than 20 to 50. The third 
problem to the strong barrier against the development of 
research in the Amazon is the Brazilian legal framework. 
The legal bureaucracy discourages and chases away scientific 
initiatives in the region. This problem is so serious that it 
prevents the implementation of scientific projects funded 
from the government budget and implemented by officials 
of the government itself. To reverse this situation concerning 
the molecular diversity description of the Amazonian 
rainforest, as a way of subsidizing the development of drugs 
to be  applied to leishmaniasis and malaria, it is necessary 
to associate conventional phytochemistry methods, HTS 
and combinatorial chemistry from both research institutes 
and industry and they must be supported by rational 
governmental policies including financial and legal efforts 
to minimize the structural and bureaucratic barriers. 
The creation of the Biodiversity and Biotechnology Web 
of the Legal Amazonia (Rede Bionorte) by the Brazilian 
Minister of Science e Technology is a very good example 
of public policy for Amazonian NCE exploration. This web 
has the objective of coordinating and generating financial 
support for research projects to be developed in Amazonia 
only by existing regional institutions and research groups. 
The incentive politics to finance projects can be the first 
step to stimulate the scientific development of this region 
through the implantation of new institutions of research and 
the reinforcement of those already existing. The Bionorte 
web is an important way of Amazonian biodiversity 
preservation and its model should be adjusted for others 
strategic scientific and political areas for Amazonian 
development.
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